Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

BACKGROUND: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally ad...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Gastrointest Oncol
Autors principals: Saif, Muhammad Wasif, Parikh, Rohan, Ray, David, Kaye, James A., Kurosky, Samantha K., Thomas, Katharine, Ramirez, Robert A., Halfdanarson, Thorvardur R., Beveridge, Thomas J. R., Mirakhur, Beloo, Nagar, Saurabh P., Soares, Heloisa P.
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657323/
https://ncbi.nlm.nih.gov/pubmed/31392048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.03.11
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars